Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03138538 · ClinicalTrials.gov registry record · Phase 1
M8891 First in Human in Solid Tumors
A Phase 1 study, sponsored by EMD Serono Research & Development Institute.
- Terminated
- Registry status
- Phase 1
- Development phase
- 27
- Enrollment target
NCT03138538 is a Phase 1 study that was terminated before completion, run by EMD Serono Research & Development Institute. The registered enrollment target is 27 participants.
The verdict
NCT03138538, a Phase 1 study, was terminated before completion, sponsored by EMD Serono Research & Development Institute.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 27 participants
- Enrollment target
Study Summary
The purpose of this study was to determine the maximum tolerated dose (MTD), safety, tolerability, Pharmacokinetic (PK), pharmacodynamic and clinical activity of M8891 as single agent in participants with advanced solid tumors in Part 1.
Interventions
- DRUG Part 1: M8891
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2017-08-08 |
| Est. Completion | 2020-09-16 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03138538
The ClinicalTrials.gov registry entry for NCT03138538 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is EMD Serono Research & Development Institute, which has 81 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Part 1: M8891 is the first listed.
NCT03138538 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03138538 about?
NCT03138538 is a clinical study titled "M8891 First in Human in Solid Tumors". The purpose of this study was to determine the maximum tolerated dose (MTD), safety, tolerability, Pharmacokinetic (PK), pharmacodynamic and clinical activity of M8891 as single agent in participants with advanced solid tumors in Part 1.
What is the current status of trial NCT03138538?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 27 participants. The study started on 2017-08-08. Estimated completion is 2020-09-16.
What interventions are being tested in trial NCT03138538?
The interventions under investigation include: Part 1: M8891 (DRUG).
Who is sponsoring clinical trial NCT03138538?
This trial is sponsored by EMD Serono Research & Development Institute, which has 81 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.